![Top 5 things to watch in markets in the week ahead](https://i-invdn-com.investing.com/news/moved_small-LYNXNPEK340EF_L.jpg)
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
CYBN | CBOE Canada | CAD | Real-time | |
CYBN | NYSE | USD | Real-time | |
R7E1 | TradeGate | EUR | Delayed |
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD) and alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation; as well as has a research pipeline of investigational psychedelic-based compounds. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.
Name | Age | Since | Title |
---|---|---|---|
Anthony Back | - | 2021 | Member of Clinical Advisory Board |
Thomas P. Laughren | - | 2021 | Member of Clinical Advisory Board |
Lynn Marie Morski | - | 2021 | Member of Clinical Advisory Board |
Maurizio Fava | - | 2021 | Member of Clinical Advisory Board |
Paul Glavine | 33 | 2020 | Co-Founder, Chief Growth Officer & Director |
Eric So | 46 | 2020 | Co-Founder, President & Executive Chairman |
Eric William Hoskins | 62 | 2020 | Independent Director |
Grant B. Froese | 61 | 2020 | Independent Director |
Theresa S. Firestone | 68 | 2021 | Lead Independent Director |
George Tziras | - | 2023 | Chief Business Officer & Director |
Mark A. Lawson | 51 | 2020 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review